New York, USA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

The advanced endometrial cancer clinical trial analysis report delivers important insights into ongoing research of 26+ pipeline advanced endometrial cancer drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Advanced Endometrial Cancer Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for advanced endometrial cancer across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the advanced endometrial cancer domain.

Advanced Endometrial Cancer Clinical Trial Analysis Summary

• DelveInsight’s advanced endometrial cancer pipeline report depicts a robust space with 25+ active players working to develop 26+ pipeline advanced endometrial cancer drugs. 
• Key advanced endometrial cancer companies, such as Pfizer, Genmab, Incyte Corporation, MacroGenics, Huabo Biopharm Co., Ltd., BioMimetix JV, LLC, Iovance Biotherapeutics, Inc., Karyopharm Therapeutics Inc., Evergreen Therapeutics, Inc., BioNTech SE, Outpace Bio, Tarapeutics Science Inc. and others, are evaluating new advanced endometrial cancer drugs to improve the treatment landscape.
• Promising pipeline advanced endometrial cancer therapies, such as PF-08634404, Rinatabart sesutecan, Retifanlimab, HB0025, BMX-001 + Paclitaxel, Lifileucel, Selinexor, EG-007, BNT329, OPB-201, TR115 and others, are in different phases of advanced endometrial cancer clinical trials.
• Approximately 8+ advanced endometrial cancer drugs are in the late and mid stages of development.
• Notable MoAs in advanced endometrial cancer clinical trials include PD-L1, VEGFR Inhibitors, XPO1 inhibition, DNA topoisomerase I inhibitors, Programmed cell death 1 receptor antagonists, Autologous tumor-infiltrating lymphocyte (TIL) replacement, NF-E2-related factor 2 stimulants, NF-kappa B inhibitors, and others.

Request a sample and discover the recent advances in advanced endometrial cancer treatment @ https://www.delveinsight.com/report-store/advanced-endometrial-cancer-pipeline-insight

What is Advanced Endometrial Cancer?

Advanced endometrial cancer refers to endometrial cancer that has spread beyond the uterus or has returned after initial treatment. It may involve nearby tissues and lymph nodes or metastasize to distant organs such as the lungs, liver, or bones. Advanced disease generally includes Stage III and Stage IV endometrial cancer, as well as recurrent disease that is no longer amenable to curative surgery or localized treatment. Treatment typically depends on factors such as disease stage, histologic subtype, molecular characteristics, and the patient’s overall health, and may include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapies, hormonal therapy, or combinations of these approaches.

Find out more about treatment for advanced endometrial cancer @ Advanced Endometrial Cancer New Treatment

A snapshot of the Pipeline Advanced Endometrial Cancer Drugs mentioned in the report:

Learn more about the advanced endometrial cancer research @ Advanced Endometrial Cancer Clinical Trials 

Stuti Mahajan, consulting manager at DelveInsight, said that advanced endometrial cancer is a challenging, often recurrent or metastatic form of disease where treatment innovation is reshaping the therapeutic landscape. The market is gaining momentum as immunotherapies, targeted agents, and ADCs emerge, broadening treatment options while driving a more competitive and increasingly biomarker-driven market.

Recent Developments in Advanced Endometrial Cancer Treatment Space

• In August 2026, Faeth Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and who have previously been treated with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI).
• In May 2026, Merck announced the pivotal Phase III TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, met its primary endpoints of overall survival (OS) and progression-free survival (PFS) in certain patients with advanced or recurrent endometrial cancer.
• In April 2026, BioNTech SE announced positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment.
• In February 2026, Sensei Biotherapeutics, Inc. announced that it has acquired Faeth Therapeutics Inc. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei’s pipeline.
• In October 2025, Genmab A/S announced updated data from cohort B2 of the Phase I/II RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor.
• In August 2025, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive EC who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.

Scope of the Advanced Endometrial Cancer Pipeline Report 

• Coverage: Global 
• Advanced Endometrial Cancer Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Advanced Endometrial Cancer Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Endometrial Cancer Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Advanced Endometrial Cancer Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Advanced Endometrial Cancer Therapeutics Assessment By Mechanism of Action:  PD-L1, VEGFR Inhibitors, XPO1 inhibition, DNA topoisomerase I inhibitors, Programmed cell death 1 receptor antagonists, Autologous tumor-infiltrating lymphocyte (TIL) replacement, NF-E2-related factor 2 stimulants, NF-kappa B inhibitors, and others
• Key Advanced Endometrial Cancer Companies: Pfizer, Genmab, Incyte Corporation, MacroGenics, Huabo Biopharm Co., Ltd., BioMimetix JV, LLC, Iovance Biotherapeutics, Inc., Karyopharm Therapeutics Inc., Evergreen Therapeutics, Inc., BioNTech SE, Outpace Bio, Tarapeutics Science Inc., and others.
• Key Advanced Endometrial Cancer Pipeline Therapies: PF-08634404, Rinatabart sesutecan, Retifanlimab, HB0025, BMX-001 + Paclitaxel, Lifileucel, Selinexor, EG-007, BNT329, OPB-201, TR115, and others.

Dive deep into rich insights for advanced endometrial cancer cure, visit @ Advanced Endometrial Cancer News

Table of Contents

For further information on the advanced endometrial cancer clinical trials, reach out @ Advanced Endometrial Cancer Medication

Related Reports

Endometrial Cancer Market

Advanced Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including Merck, Karyopharm Therapeutics, AstraZeneca, Daiichi Sankyo, Faeth Therapeutics, Hoffmann-La Roche, Iovance Biotherapeutics, and others.

Endometrial Cancer Clinical Trial Analysis

Endometrial Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometrial cancer companies, including Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, among others.

Endometriosis Market

Endometriosis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key endometriosis companies, including Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon, and others.

Endometriosis Clinical Trial Analysis 

Endometriosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Hope Medicine (Nanjing) Co., Ltd, TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.

Endometriosis Pain Market

Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679